Microsatellite instability status
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-MSI-STATUS |
|---|---|
| Type | Biomarker |
| Aliases | MSIMSI status (MSI-H / MSI-L / MSS)Microsatellite instabilityСтатус мікросателітної нестабільності |
| Status | reviewed 2026-04-26 |
| Diseases | None declared |
| Sources | SRC-NCCN-COLON-2025 SRC-NCCN-GASTRIC-2025 |
Biomarker Facts
| Biomarker type | msi_status |
|---|---|
| Measurement | MethodPCR-based 5-marker panel (BAT-25, BAT-26, NR-21, NR-24, MONO-27) OR NGS-derived MSIsensor / MANTIS / mSINGS Unitscategorical: MSI-H (≥2 of 5 markers unstable, or NGS score ≥10) | MSI-L | MSS Roundingcategorical |
| Related biomarkers | BIO-DMMR-IHC |
Used By
Actionability
BMA-MSI-STATUS-CRC- MSI-H (microsatellite instability-high) CRC is the primary biomarker for first-line pembr...BMA-MSI-STATUS-ENDOMETRIAL- MSI-H/dMMR endometrial cancer (~25-30% of advanced cases) qualifies for ICI-based regimen...BMA-MSI-STATUS-GASTRIC- MSI-H gastric/GEJ adenocarcinoma (~5-10% of cases) is associated with improved response t...
Biomarker
BIO-CLDN18-2- Claudin-18.2 expression (CLDN18.2)BIO-DMMR-IHC- Mismatch repair protein expression by IHCBIO-FGFR2B-IHC- FGFR2b protein expression by IHC (membranous staining)BIO-LYNCH-PANEL-SPLIT- Lynch syndrome germline panel — gene-resolved (MLH1 / MSH2 / MSH6 / PMS2 / EPCAM)BIO-POLD1-HYPERMUTATOR- POLD1 hypermutator phenotype (proofreading-domain mutation)BIO-POLE-HYPERMUTATOR- POLE hypermutator phenotype (proofreading-domain mutation)BIO-TMB-HIGH- Tumor mutational burden (TMB-high)BIO-TP53-IHC- TP53 IHC (aberrant p53 expression pattern)
Diseases
DIS-CHOLANGIOCARCINOMA- Cholangiocarcinoma (bile duct cancer)DIS-HNSCC- Head and neck squamous cell carcinoma (HNSCC)
Indications
IND-CRC-3L-FRUQUINTINIB- IND-CRC-3L-FRUQUINTINIBIND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX- IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOXIND-CRC-METASTATIC-1L-FOLFOX-BEV- IND-CRC-METASTATIC-1L-FOLFOX-BEVIND-CRC-METASTATIC-1L-FOLFOXIRI-BEV- IND-CRC-METASTATIC-1L-FOLFOXIRI-BEVIND-CRC-METASTATIC-1L-MSI-H-PEMBRO- IND-CRC-METASTATIC-1L-MSI-H-PEMBROIND-CRC-METASTATIC-1L-RAS-WT-LEFT- IND-CRC-METASTATIC-1L-RAS-WT-LEFTIND-CRC-METASTATIC-2L-EGFRI-RECHALLENGE- IND-CRC-METASTATIC-2L-EGFRI-RECHALLENGEIND-CRC-METASTATIC-2L-FOLFIRI-BEV- IND-CRC-METASTATIC-2L-FOLFIRI-BEVIND-CRC-METASTATIC-2L-HER2-AMP-T-DXD- IND-CRC-METASTATIC-2L-HER2-AMP-T-DXDIND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIB- IND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIBIND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMAB- IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMABIND-CRC-METASTATIC-2L-MSI-H-PEMBRO- IND-CRC-METASTATIC-2L-MSI-H-PEMBROIND-CRC-METASTATIC-3L-REGORAFENIB- IND-CRC-METASTATIC-3L-REGORAFENIBIND-CRC-METASTATIC-3L-TAS102-BEV- IND-CRC-METASTATIC-3L-TAS102-BEVIND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONO- IND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONOIND-CRC-METASTATIC-MAINT-FOLFIRI-BEV- IND-CRC-METASTATIC-MAINT-FOLFIRI-BEVIND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB- IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMABIND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB- IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB
Questionnaires
QUEST-CRC-1L-STUB- Colorectal carcinoma — first line
Red flag
RF-ENDOMETRIAL-HIGH-RISK-BIOLOGY- dMMR/MSI-high OR p53-abnormal OR POLE-mutated — TCGA classification drives ICI eligibilit...